NHF received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab).
↧
NHF received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab).